These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 26451607)

  • 1. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells.
    Yuan CH; Sun XM; Zhu CL; Liu SP; Wu L; Chen H; Feng MH; Wu K; Wang FB
    Oncotarget; 2015 Oct; 6(31):32138-53. PubMed ID: 26451607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
    Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
    Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
    Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
    Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
    Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
    Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoma cell-derived leptin downregulates the immunosuppressive function of regulatory T-cells to enhance the anti-tumor activity of CD8+ T-cells.
    Wei R; Hu Y; Dong F; Xu X; Hu A; Gao G
    Immunol Cell Biol; 2016 Apr; 94(4):388-99. PubMed ID: 26639061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients.
    Wu H; Chen P; Liao R; Li YW; Yi Y; Wang JX; Cai XY; He HW; Jin JJ; Cheng YF; Fan J; Sun J; Qiu SJ
    J Gastroenterol Hepatol; 2013 Sep; 28(9):1555-64. PubMed ID: 23517245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
    Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
    Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased frequency of Foxp3+ regulatory T cells in mice with hepatocellular carcinoma.
    Du Y; Chen X; Huang ZM; Ye XH; Niu Q
    Asian Pac J Cancer Prev; 2012; 13(8):3815-9. PubMed ID: 23098476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice.
    Zhao W; Zhang L; Yin Z; Su W; Ren G; Zhou C; You J; Fan J; Wang X
    Int J Cancer; 2011 Dec; 129(11):2651-61. PubMed ID: 21213212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
    Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
    Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients].
    Zhang HH; Fei R; Xie XW; Wang L; Luo H; Wang XY; Wei L; Chen HS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 41(3):313-8. PubMed ID: 19727215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide is an immune adjuvant in liver cancer treatment.
    Wang L; Wang R; Fan L; Liang W; Liang K; Xu Y; Peng G; Ye Q
    Mol Immunol; 2017 Jan; 81():118-126. PubMed ID: 27940255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
    van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
    Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma.
    Yang XH; Yamagiwa S; Ichida T; Matsuda Y; Sugahara S; Watanabe H; Sato Y; Abo T; Horwitz DA; Aoyagi Y
    J Hepatol; 2006 Aug; 45(2):254-62. PubMed ID: 16600416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells.
    Wang LK; Kuang M; Hua YP; He Q; Chen B; Wang Y; Peng BG
    J Surg Res; 2013 Aug; 183(2):900-6. PubMed ID: 23481561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
    Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS
    Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
    Gao Q; Qiu SJ; Fan J; Zhou J; Wang XY; Xiao YS; Xu Y; Li YW; Tang ZY
    J Clin Oncol; 2007 Jun; 25(18):2586-93. PubMed ID: 17577038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma.
    Huang Y; Wang F; Wang Y; Zhu Z; Gao Y; Ma Z; Xu R; Du Z
    J Gastroenterol Hepatol; 2014 Apr; 29(4):851-9. PubMed ID: 24303990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.